

**The first,
patented
and best-researched
butyrate on the market.**


1



MSB® safety and efficacy proven by:


- » **6 clinical studies** involving more than **3.300 patients**
- » **10 years** of clinical research in IBS, IBD, diverticular disease, SIBO, diabetes type 2
- » continued research in **gastrointestinal** and **metabolic** disorders.

Different release profiles and dosages mean that various products may have distinctly different effects on intestinal function.



Comparative in vitro release study of different sodium butyrate formulations* has shown that the **release profiles of different sodium butyrate formulations differ significantly.**

The original and patented MSB® technology provides gradual and even release of butyrate in the duodenum, jejunum, ileum, and colon, distinguishing it from other products.



Intestinal disorders and diseases affect both the small and large intestine.

MSB® gradual and sustained release of butyrate is crucial for achieving clinical effects, as butyrate is rapidly and efficiently utilized at the release site by epithelial cells.

The high efficacy and safety of products using MSB® butyrate has been confirmed in 6 clinical trials involving over 3.300 patients.

Disease	Study	No. of patients	Comments
IBS	2011, Tarnowski et al.	59	6 weeks of supplementation, 2x 150 mg daily. Effects: decreased severity of IBS symptoms including discomfort, abdominal pain, and bowel movement disorders.
IBS	2012, Banasiewicz et al.	66	12 weeks of supplementation, 2x 150 mg daily. Effects: decreased severity of IBS symptoms including discomfort and abdominal pain.
IBS	2022, Lewandowski et al.	3000	12 weeks of supplementation, 2x 150 mg daily. Effects: decreased frequency and severity of IBS symptoms including abdominal pain, constipation, diarrhea, bloating, improved quality of life and treatment satisfaction.
IBD (UC, Crohn's disease in children)	2025, Goldis et al.	88	12 weeks of supplementation, 1x 150 mg daily. Effects: decreased disease activity, reduced calprotectin and CRP levels.
UC, diverticular disease	2013, Krokowicz et al.	52	Observation after 12 months of study, 2x 150 mg daily. Effects – decreased frequency of diverticulitis occurrence.
SIBO	2024, Panufnik et al.	52	12 weeks of supplementation, 2x 750 mg daily. Effects: decreased severity of abdominal symptoms, SIBO, decreased HbA1c, and BMI.
Type 2 diabetes with abdominal symptoms (including SIBO)	2024, Panufnik et al.		

Due to significant differences in release profiles and sodium butyrate doses, the study results apply exclusively to MSB® and not to other butyrate formulations.

MSB® original technology, ensuring sustained and targeted release of butyrate along the entire length of the intestines, is protected by Polish and European patents.

